Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- PharmaEssentia Lays Out Sales Organization in Japan for 1st Product Launch
February 20, 2023
- Susmed Bags Japan Approval for Insomnia App
February 20, 2023
- IQVIA Pledges Push to Biopharma Startups in Japan
February 20, 2023
- Global PIII Launched for Xocova in Hospitalized Patients: Shionogi
February 20, 2023
- Mitsubishi Chemical Ups Full-Year Outlook on Gilenya Royalty Win
February 20, 2023
- Shareholders OK Nichi-Iko’s Delisting, Turnaround under New Management; President to Exit March 8
February 20, 2023
- Healios Cuts 40 % of Employees Due to MultiStem Development Glitches
February 17, 2023
- Nippon Shinyaku Grabs Japan Rights to Capricor’s DMD Cell Therapy
February 17, 2023
- ViiV Eyes More Uptake for Japan’s 1st Long-Acting HIV Med, Revs Up Development Drive
February 17, 2023
- As Global Race Heats Up for RAS Drugs, Japan Players Joining Fray with New Modalities
February 15, 2023
- Mitsubishi Tanabe Wins Arbitration Case over Gilenya Royalty
February 15, 2023
- Otsuka’s Pharma Sales Up 16.4% in 2022 on Global Brands, Hits 2023 Target 1 Year Earlier
February 15, 2023
- Fujifilm Begins Japan PIII for Stem Cell Therapy in Meniscus Injuries
February 15, 2023
- Mitsubishi Chemical Scraps Muse Cell Therapy Program
February 15, 2023
- Sawai President Sounds Negative about M&As, but Agrees Generic Industry Needs Consolidation
February 14, 2023
- Asahi Kasei Pharma Poised for a String of Approvals and Launch in 2023
February 14, 2023
- Sawai President Declares Plan to Raise Shipment Prices in FY2023
February 14, 2023
- Zeria to Take over Japan Marketing Authorization for Dafclir from Astellas
February 14, 2023
- AbbVie Rolls Out Skyrizi Auto-Doser in Japan
February 14, 2023
- Adcetris Filed for CTCL Indication in Japan: Takeda
February 14, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…